Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Splits Company with AbbVie Spinout

NEW YORK (GenomeWeb News) – Abbott said today that it has completed the separation of its research-based pharmaceutical business, which has been spun out into a publicly traded entity called AbbVie.

Abbott announced its plans to split the company into two separate, publicly-traded companies — one focused on diversified medical products and the other on research-based pharmaceuticals — in October 2011.

In late November Abbott's board of directors declared a special dividend distribution of all outstanding shares of AbbVie stock. For every one share of Abbott common shares held, Abbott shareholders received one share of AbbVie common stock on Jan. 1.

Abbott said that it is now composed of four businesses — diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals — all of roughly equal size.

Abbott Chairman and CEO Miles White said that the split is "the most transformative action" in Abbott's 125-year history.

In Wednesday morning trade on the New York Stock Exchange shares of Abbott were up 1 percent at $31.79.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.